Recent events
Recent events tied to this brand in public sources.
Back to profile9 entries
2021
New Kaiyuan and Abcam strategic partnership
New Kaiyuan and Abcam formally signed a strategic cooperation agreement covering the supply and licensing of affinity reagents and custom services for New Kaiyuan's in-vitro diagnostics product development and commercialization.
2021
Abcam completes acquisition of BioVision
Abcam announced the successful completion of its acquisition of BioVision, bringing BioVision’s product portfolio, capabilities, and development and manufacturing teams into Abcam.
2021
Abcam expands immunoassay facility capacity in Eugene
Abcam announced that it had doubled the footprint of its immunoassay kit research and development and manufacturing facility in Eugene, Oregon.
2021
Abcam and Pionyr expand commercial licensing collaboration
Abcam and Pionyr announced that they had signed a new commercial license agreement expanding their collaboration to support Pionyr's PY314 entering clinical development. Pionyr will use Abcam's TREM2 antibody to test tumor biopsy samples and explore development of a companion diagnostic.
2021
Abcam receives CiteAb cardiovascular research award
Abcam received CiteAb's “Antibody Supplier Succeeding in Cardiovascular Research” award.
2020
Abcam completes acquisition of MarkerGene Technologies
Abcam completed its acquisition of all issued share capital of MarkerGene Technologies, expanding Abcam’s assay development technology and labeling capabilities.
2020
Abcam completed acquisition of Applied StemCell assets
Abcam completed the acquisition of Applied StemCell's gene-editing platform and oncology product portfolio for the life sciences research and diagnostics markets on January 28, 2020.
2020
Abcam completes acquisition of Expedeon's Proteomics and Immunology business
Abcam completed the acquisition of Expedeon's Proteomics and Immunology business, including Innova and TGR Biosciences, as of January 1, 2020.
2020
Abcam completes acquisition of Expedeon's proteomics and immunology business
Abcam completed its acquisition of Expedeon's proteomics and immunology business, including Innova and TGR Biosciences, on January 1, 2020.